BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
To access the webcast via the internet, log on to http://www.biocryst.com.Please connect to the website at least 15 minutes prior to the conference callto ensure adequate time for any software download that may be needed to hearthe webcast. Alternately, please call 1-800-860-2442 (U.S.) or 1-412-858-4600(international). Telephone replay will be available. To access the replay,please call 1-877-344-7529 (U.S.) or 1-412-317-0088 (international) and dialthe participant passcode 413134#. The webcast will be archived onhttps://www.biocryst.com.
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallographyand structure-based drug design for the development of novel therapeutics totreat cancer, cardiovascular diseases, autoimmune diseases, and viralinfections. The company is advancing multiple internal programs towardpotential commercialization including forodesine HCl in oncology, BCX-4208 intransplantation and autoimmune diseases and peramivir in seasonal and life-threatening influenza. BioCryst has a worldwide partnership with Roche for thedevelopment and commercialization of BCX-4208, and is collaborating withMundipharma for the development and commercialization of forodesine HCl inmarkets across Europe, Asia, Australia and certain neighboring countries. InJanuary, 2007 the U.S. Department of Health and Human Services (DHHS) awardeda $102.6 million, four-year contract to BioCryst for advanced development ofperamivir to treat seasonal and life-threatening influenza. In February 2007BioCryst established a partnership with Shionogi & Co., to develop andcommercialize peramivir in Japan. For more information about BioCryst, pleasevisit the company's web site at http://www.biocryst.com.
This press release contains forward-looking statements, includingstatements regarding future results, performance or achievements. Thesestatements involve known and unknown risks, uncertainties and other factorswhich may cause our actual results, performance or achievements to bematerially different from any future results, performances or achievementsexpressed or implied by the forward-looking statements. These statementsreflect our current views with respect to future events and are based onassumptions and subject to risks and uncertainties. Given these uncertainties,you should not place undue reliance on these forward-looking statements. Someof the factors that could affect the forward-looking statements containedherein include that our belief that many subjects in the Phase II clinicaltrials of peramivir did not receive adequate dosing by i.m. injection may notbe correct, that final results and analysis of the peramivir Phase II trialmay differ from the preliminary results and analysis, that DHHS and the FDAmay not agree with our analysis, that DHHS may further condition, reduce oreliminate future funding of the peramivir program, that we may not commence intimely fashion or at all the planned Phase III trial for peramivir and ifcommenced, it may not be successful, that the pivotal trial with forodesineHCl in CTCL may not meet its endpoint, that the Phase II trial of BCX-4208 forpsoriasis may not be successfully completed, that development andcommercialization of forodesine HCl in both T-ALL and CTCL may not besuccessful, that we may not resolve sati
You May Also Like